Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Case Study Using PBPK for Label Recommendations in Rare Disease: Deflazacort for Duchenne Muscular Dystrophy Jim Gallagher2021 年 8 月 20 日
Immunogenicity Prediction and Dose Optimization using Clinically-Validated In Silico Modeling & Simulation White Paper 使用经临床验证的计算机建模和模拟进行免疫原性预测和剂量优化 Jim Gallagher2021 年 8 月 19 日
How New FDA Guidance Project Optimus May Affect Future of Oncology Clinical Trials, Drug Pipeline Article 全新 FDA 指南 Project Optimus 可能如何影响肿瘤学临床试验和药物研究计划的未来 Julie Bullock, VP, global head of clinical pharmacology and translational medicine at Certara, discusses the…Certara2021 年 8 月 16 日
Gene Therapy Based Precision Medicine Therapeutics: Clinical Pharmacology & Translational Science Considerations Blog Gene Therapy Based Precision Medicine Therapeutics: Clinical Pharmacology & Translational Science Considerations The era of gene therapy may have started a couple of decades ago, but approvals…Certara2021 年 8 月 13 日
生物制剂的临床药理计划是怎样的? 网络研讨会点播 生物制剂的临床药理计划是怎样的? Monoclonal antibodies are now widely used in the treatment of several diseases, providing effective and…Jim Gallagher2021 年 8 月 6 日
Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data Press Release Certara to Acquire Pinnacle 21, a Leader in Data Standardization Software for Pharmaceutical Clinical Data Transaction expected to be accretive to Certara’s revenue, revenue growth and adjusted EBITDA margin Princeton,…Jim Gallagher2021 年 8 月 5 日
Succeeding in Value Communication: Introduction Blog 价值沟通制胜之道:导言 Drawn from the experiences of the BaseCase Consulting Team, this is the introduction to ‘Succeeding…Certara2021 年 8 月 5 日
Application of Quantitative Systems Pharmacology to guide the optimal dosing of COVID-19 vaccines Publication 应用定量系统药理学(QSP)指导 COVID-19 疫苗最佳剂量方案 Optimal use and distribution of coronavirus disease 2019 (COVID-19) vaccines involves adjustments of dosing. Due…Jim Gallagher2021 年 7 月 31 日
PBPK Modeling of Tizanidine Systemic Exposure by CYP1A2 Modulation: Impact of DDIs & Smoking On-Demand Webinar PBPK Modeling of Tizanidine Systemic Exposure by CYP1A2 Modulation: Impact of DDIs & Smoking This webinar was presented on 2021 年 6 月 30 日 by David R. Taft, Ph.D. Professor, Pharmaceutics,…Jim Gallagher2021 年 7 月 26 日